NCT04158258 2026-02-12
A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
Hoffmann-La Roche
Active not recruiting
Clinical Trials
13 trialsNCT06961331 2026-01-09
Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.
Pfizer
Completed
NCT02771795 2024-02-02
A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC
Samsung Bioepis Co., Ltd.
Terminated
NCT06021379 2023-10-31
AryoTrust® (Trastuzumab) Safety Study
AryoGen Pharmed Co.
Completed
NCT03521245 2021-09-14
Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer
OmicsWay Corp.
Unknown
NCT01959386 2020-03-03
HerSCin
Hoffmann-La Roche
Completed
NCT00833963 2019-05-16
MotHER
Genentech, Inc.
Completed
NCT01839500 2018-03-29
EVIDENCE
Hoffmann-La Roche
Completed
NCT01152606 2018-01-25
A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin
Hoffmann-La Roche
Completed
NCT01187381 2017-10-20
HERODOT
Hoffmann-La Roche
Terminated
NCT01480674 2017-08-16
An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years
Hoffmann-La Roche
Completed
NCT02658461 2016-04-29
An Observational Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (EBC)
Hoffmann-La Roche
Completed
NCT01077648 2014-05-26
Brain Metastasis in Breast Cancer Patients
GlaxoSmithKline
Completed